A multi-center prospective randomized controlled study for Jiedu Granule in the treatment of advanced hepatocellular carcinoma
- Conditions
- Hepatocellular carcinoma
- Registration Number
- ITMCTR1900002303
- Lead Sponsor
- Changhai Hospital of Traditional Chinese Medicine,Navy Military Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Male or female aged older than 18 years;
2. Histologically diagnosed HCC, OR clinically diagnosed HCC;
3. Documented progression with or intolerance to target therapy for advanced HCC and no indication of transarterial chemoembolization and radiotherapy;
4. Stage C and D according to the BCLC staging classification;
5. More than 1 month from the last TACE or 2 months from the last radiotherapy.
6. The estimated survival time is more than 2 months;
7. Willing to participate in clinical trials and sign informed consent.
1. currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment;
2. Local treatment including radiotherapy (except palliative radiotherapy), percutaneous ethanol injection, radiofrequency ablation, transarterial embolization, or cryotherapy administered within 4 weeks prior to enrollment;
3. Had a solid organ transplant;
4. Presence of brain or leptomeningeal metastases;
5. Has had esophageal or gastric variceal bleeding within the last 6 months;
6. the researchers consider those who were not suitable for inclusion.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival;
- Secondary Outcome Measures
Name Time Method